Tracer library / [89Zr]Zr-Df-IgG-800CW
[89Zr]Zr-Df-IgG-800CW
Also written as Df-IgG-800CW; Zr-89 Df-IgG-800CW; Zr-89-Df-IgG-800CW
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- PET
- Production route
- â
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- Nonspecific IgG antibody dual-labeled with desferrioxamine (89Zr chelator) and IRDye 800CW fluorophore
- Target / mechanism
- â
- Clinical application
- Ovarian cancer - nonspecific control tracer for preoperative imaging and image-guided surgery PMID 31392081
- Theranostic pair
- â
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [89Zr]Zr-Df-IgG-800CW, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [89Zr]Zr-Df-IgG-800CW.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Zr-89. Stage 25: this agent has NO own synthesis/characterisation data in the current corpus -- none of the linked articles mention this compound at all -- each is about a different Zr-89/225Ac-labelled antibody conjugate. All previously-linked runs were unlinked (see parsed-therapy.xlsx). Stage set/updated at stage 39 from PMID 31392081: 'For PET imaging in subcutaneous xenograft ovarian cancer models, 89Zr-Df-pertuzumab-800CW showed a significantly higher tumor-to-muscle ratio compared to the nonspecific 89Zr-Df-IgG-800CW'.